15 / 20
Page 48
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Clin Trial
ISSN: 2167-0870 JCTR, an open access journal
Global Pharmacovigilance 2017
July 06-07, 2017
JULY 06-07, 2017 KUALA LUMPUR, MALAYSIA
8
TH
GLOBAL
Pharmacovigilance &
Drug Safety Summit
J Clin Trial 2017, 7:4 (Suppl)
DOI: 10.4172/2167-0870-C1-017
Effects of Vinpocetine and Isosorbide-5-mononitrate on experimental Schistosomiasis mansoni,
parasitological and histopathological study
Samar Nagah El-Beshbishi, Samar M Alhusseiny, Maha M Abu Hashim, Hosam El-dein E El-nemr and Aya E Handoussa
Mansoura University, Egypt
Background:
Schistosomiasis is a major public health problem in developing countries. Currently, praziquantel (PZQ) is the
drug of choice for human schistosomiasis. Owing to the increasingly recognized PZQ resistance, there is an urgent need to
develop new alternatives.
Methodology:
The anti-schistosomal and/or the hepatoprotective efficacy of the anti-inflammatory drug; Vinpocetine, and
the vasodilator and the nitric oxide (NO) donor; Isosorbide-5-mononitrate (IS-5-MN) were assessed in Schistosoma mansoni-
infected mice, using some parasitological, and histopathological parameters.
Findings:
PZQ significantly increased the percentage of dead eggs and decreased granuloma count, but did not reduce
granuloma diameter while, either vinpocetine or IS-5-MN significantly reduced granuloma count and diameter. Moreover,
IS-5-MN monotherapy significantly reduced hepatic inflammation and necrosis. The best results were obtained in the mice
groups treated with IS-5-MN combined with PZQ or Vinpocetine.
Conclusion & Significance:
Our results point to Vinpocetine and IS-5-MN as a convenient and promising adjuvant agents to
PZQ to ameliorate schistosomal liver pathology. Future studies are recommended to reveal the actual pathways responsible for
all different activities of Vinpocetine and IS-5-MN.
selbeshbishi@gmail.com